Vir Biotechnology, Inc. — Form 8-K
Filed October 28, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 23/100
What the filing says
The 8-K discloses Item 5.02 regarding departure of directors or officers and compensatory arrangements, filed on 2026-10-28 with period of report 2026-10-26. The filing header and document index are present, but the substantive text detailing the officer names, compensation amounts, or specific arrangements is not provided in the submitted filing text.
Why this rating
Officer compensation arrangements are routine disclosures; without specifics (names, amounts, vesting, role), cannot assess materiality relative to $689M market cap.
Extracted items
See more from October 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.